The global meningococcal vaccine market size valued at $ 2.77 billion in 2020 and expected to reach $ 5.92 billion in 2027, growing at a CAGR of 9.14% from 2021 to 2027. Meningococcal disease is a fatal disease caused by a bacteria called as Neisseria Meningitides which cause potential infection in the meninges, the thin layers of connective tissues which surrounds spinal cord and brain. Common symptoms are bacteraemia, pneumonia and meningitis associated with neck stiffness, nausea, high fever, vomiting, confusion, rashes and lethargy. Surge in incidence of meningococcal disease is expected to play vital role in growth of the global meningococcal vaccines market. Meningococcal meningitis is a major public health concern. Various treatment approaches with reasonable costs have been established, however they continue to result in a high fatality rate. In newborns and young children, they can have long-term neurological repercussions. According to a WHO estimate, 50 percent of meningitis cases occur in children under the age of five. The next susceptible age group is 15-19 years. Meningitis has had such a negative impact on humanity that various multinational private agencies have stepped up to create a vaccine. Meningococcal vaccines are available in four different categories. Meningitis A (MenA) and three Conjugate MenACWY vaccines are available. Furthermore, growing awareness among the people regarding the seriousness of disease, government initiatives, increase R&D investments by various players, introduction of advanced vaccines are expected to boost growth of meningococcal vaccines market. However, lack of awareness, high cost of vaccines, unfavourable regulatory conditions are restrains of global meningococcal vaccines market.